Provisions in the upcoming user fee reauthorization bill may already be in development as a bipartisan group in the House of Representatives requested updates on the US Food and Drug Administration’s complex generic drug approval process.
A 17 January letter to FDA Commissioner Stephen Hahn from majority and minority leaders of the House Energy and...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?